Clinical trials: Early Alzheimers Disease
Alzheimer Disease, Alzheimer Disease, Early Onset
A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)
The purpose of this study (Bio-Hermes) is to develop a blood, digital, and brain amyloid PET scan biomarker database that can be used to determine whether a meaningful relationship exists between digital tests, blood…
- Conditions
- Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss
- Trial name
- NCT04733989
- Testing
- Biomarker Data Collection
- Where
- 16 sites in United States
- Volunteers
- 1,002 people
- Sponsor
- GAP Innovations, PBC
Cognitive Decline, Mild, Alzheimer Disease
Fasudil Trial for Treatment of Early Alzheimer's Disease (FEAD)
The goal of this placebo-controlled double-blind Phase 2 clinical trial is to test in people with early Alzheimer's Disease. The main questions it aims to answer are: Does treatment with fasudil, a ROCK-inhibitor, lead to…
- Trial name
- FEAD (NCT06362707)
- Testing
- Fasudil
- Where
- 6 sites in Norway
- Volunteers
- 200 people
- Sponsor
- Helse Stavanger HF
Neurocognitive Disorders
Early Detection of Alzheimer's Disease and Affective Disorders by Automated Voice and Speech Analysis (PLATA)
PLATA aims to develop an algorithm to identify vocal biomarkers of Alzheimer's dementia. Using data collected as part of routine care, speech patterns will be compared to known biomarkers of Alzheimer's disease, such as amyloid…
- Trial name
- PLATA (NCT05943834)
- Testing
- Series of cognitive tasks during a semi-automated call
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Dementia
Efficacy of 1072nm Infrared Stimulation on Executive Functioning in Dementia
This study will employ a double-blind, placebo-controlled approach to assess the effect of 1072nm infrared (IR) phototherapy on the behavioral and cognitive symptoms associated with early and mid-stage dementia.
- Trial name
- NCT01059877
- Testing
- 1072nm infrared Photobiomodulation, Photobiomodulation SIMULATED
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Quietmind Foundation
Mild Cognitive Impairment, Alzheimer Disease
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Dementia
The purpose of this study is to investigate whether a blood pressure medication, spironolactone, can be tolerated by older African American adults that have memory and thinking problems, also called mild cognitive impairment…
- Trial name
- STAND (NCT04522739)
- Testing
- Spironolactone
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Emory University
Alzheimer Disease
Tau Screening Study in Subjects With Early Symptomatic AD
This protocol is designed to serve as a pre-screening study for subjects who are potentially eligible for Alzheimer's Disease (AD) therapeutic trials that require tau imaging for inclusion by means of a flortaucipir F18 Positron…
- Trial name
- NCT03467477
- Testing
- Flortaucipir F18, Brain PET Scan
- Where
- 9 sites in United States
- Volunteers
- 161 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease, Mild Cognitive Impairment
Identification of Patients With a High Probability of Meeting Eligibility Criteria for an Alzheimer's Disease Clinical Trial (APHELEIA)
Apheleia-001 is a prescreener that aims to identify and characterize participants with reported cognitive impairment using demographic information, clinical history, brief cognitive assessments, and blood-based biomarkers to…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Memory Loss, Memory Disorders
- Trial name
- NCT05364307
- Testing
- Prescreener database
- Where
- 19 sites in United States, Canada
- Volunteers
- 1,555 people
- Sponsor
- Global Alzheimer's Platform Foundation
Alzheimer's Disease
Reminiscence, Anxiety and Early Alzheimer's Disease
This study seeks to establish the acceptability and evaluate the limited efficacy of Simple Reminiscence (SR), a home-delivered non-pharmacological intervention designed to relieve stress, improve affect, and prevent or quell…
- Trial name
- NCT02319681
- Testing
- Simple Reminiscence (SR), Attention Control (AC)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
Alzheimer Disease
Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers
This proof-of-mechanism clinical trial study will test the efficacy and safety of thiethylperazine (TEP) in subjects with early onset of Alzheimer's Disease (AD).
- Trial name
- drainAD (NCT03417986)
- Testing
- TEP
- Where
- 2 sites in Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Immungenetics AG
Alzheimer's Disease
Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability
Patients with Alzheimer's disease (AD) can have seizures in addition to losing their memory and other mental functions (referred to as cognitive functions).
- Trial name
- LEV-AD (NCT02002819)
- Testing
- levetiracetam
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Minnesota
Mild Cognitive Impairment, Alzheimer's Disease
The Swedish BioFINDER Study
The present study aims at combining biochemical methods with various types of imaging techniques to identify the pathophysiology of Alzheimer's disease (AD).
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Dementia With Lewy Bodies, Vascular Dementia
- Trial name
- NCT01208675
- Where
- 2 sites in Sweden
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Alzheimer Disease, Mild Cognitive Impairment
Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease
This study investigates the effects of Valaciclovir treatment to individuals with Alzheimer's disease or Mild Cognitive Impairment of Alzheimer's Disease Type.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Herpes Simplex
- Trial name
- VALZ-Pilot (NCT02997982)
- Testing
- Valaciclovir 500Mg Tablet
- Where
- 2 sites in Sweden
- Volunteers
- 33 people
- Sponsor
- Hugo Lovheim
Alzheimer Disease, Early Onset
Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency.
- Trial name
- CHOLINE-2 (NCT04661280)
- Testing
- Donepezil
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer Disease (AD)
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
- Trial name
- NCT03518073
- Testing
- Zagotenemab
- Where
- 60 sites in United States, Canada and 1 more
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, based on…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED-PAST (NCT04851496)
- Where
- 4 sites in United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer Disease
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
- Trial name
- NCT03367403
- Testing
- Donanemab, LY3202626
- Where
- 61 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
This study is an extension of study I8D-MC-AZES (NCT02245737), the AMARANTH study. The purpose of this study is to evaluate the effectiveness of the study drug lanabecestat in participants with early Alzheimer's disease dementia…
- Trial name
- NCT02972658
- Testing
- Lanabecestat
- Where
- 133 sites in United States, Australia and 12 more
- Volunteers
- 421 people
- Sponsor
- AstraZeneca
Alzheimer Disease
Detecting an Early Response to Donepezil With Measures of Visual Attention
Acetylcholinesterase inhibitors (AChE-I) comprise a class of drugs used to treat Alzheimer's disease (AD), but controversy about their usefulness remains.
- Trial name
- NCT03073876
- Testing
- Donepezil Hydrochloride
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Alzheimer Disease, Dementia
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05508789
- Testing
- Donanemab
- Where
- 141 sites in Argentina, Australia and 6 more
- Volunteers
- 1,500 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
This is a Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Multiple Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers and Subjects with MCI or…
- Trial name
- NCT06194552
- Testing
- NTRX-07
- Where
- 2 sites in United States, Hungary
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- NeuroTherapia, Inc.